- Home
- ASUR vs MRSN Comparison
ASUR vs MRSN Comparison
Compare ASUR & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASUR
- MRSN
- Stock Information
- Founded
- ASUR 1985
- MRSN 2001
- Country
- ASUR United States
- MRSN United States
- Employees
- ASUR N/A
- MRSN N/A
- Industry
- ASUR EDP Services
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- ASUR Technology
- MRSN Health Care
- Exchange
- ASUR Nasdaq
- MRSN Nasdaq
- Market Cap
- ASUR 246.3M
- MRSN 252.0M
- IPO Year
- ASUR 1992
- MRSN 2017
- Fundamental
- Price
- ASUR $9.07
- MRSN $1.61
- Analyst Decision
- ASUR Strong Buy
- MRSN Buy
- Analyst Count
- ASUR 7
- MRSN 6
- Target Price
- ASUR $13.14
- MRSN $6.00
- AVG Volume (30 Days)
- ASUR 113.6K
- MRSN 1.3M
- Earning Date
- ASUR 10-31-2024
- MRSN 11-13-2024
- Dividend Yield
- ASUR N/A
- MRSN N/A
- EPS Growth
- ASUR N/A
- MRSN N/A
- EPS
- ASUR N/A
- MRSN N/A
- Revenue
- ASUR $115,264,000.00
- MRSN $34,837,000.00
- Revenue This Year
- ASUR $2.63
- MRSN N/A
- Revenue Next Year
- ASUR $12.38
- MRSN N/A
- P/E Ratio
- ASUR N/A
- MRSN N/A
- Revenue Growth
- ASUR N/A
- MRSN N/A
- 52 Week Low
- ASUR $6.89
- MRSN $1.22
- 52 Week High
- ASUR $10.52
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- ASUR 46.02
- MRSN 37.05
- Support Level
- ASUR $9.29
- MRSN $2.37
- Resistance Level
- ASUR $9.54
- MRSN $2.81
- Average True Range (ATR)
- ASUR 0.38
- MRSN 0.27
- MACD
- ASUR -0.04
- MRSN -0.08
- Stochastic Oscillator
- ASUR 22.35
- MRSN 11.03
About ASUR Asure Software Inc
Asure Software Inc is a provider of cloud-based Human Capital Management (HCM) solutions delivered as Software-as-a-Service (SaaS). It facilitates small and mid-sized businesses (SMBs) to develop their Human Capital to get to the next level, stay compliant, and allocate their time, money and technology toward growth. The company's HCM suite, named AsureHCM, includes cloud-based Payroll and Tax, HR, a Time and Attendance software. Its HR services range from HR projects to outsourcing payroll to HR consulting services. The firm sells its HCM products majorly in the United States.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.